Seeking Alpha

Array (ARRY -14.8%) takes a pounding after its ARRY-797 drug failed to reduce pain better than...

Array (ARRY -14.8%) takes a pounding after its ARRY-797 drug failed to reduce pain better than an existing standard treatment, Oxycodone, in a Phase II trial of osteoarthritis patients. However, ARRY-797 did did meet its primary endpoints and reduced pain much more than a placebo. (PR)
Comments (1)
  • kuma
    , contributor
    Comments (2) | Send Message
     
    As an MD I can tell you that ARRAY 797, if it continues to prove to be as safe and as effective as it was in the recent study, then it will be a huge blockbuster of a drug. The ability to relieve pain as well as narcotics (the gold standard in pain relief) plus NSAIDS is phenomenal, particularly with fewer side-effects. I think ARRY is demonstrating that they know how to design drugs that work and surely pharmaceutical companies are going to line up to partner on such a potentially profitable new drug.
    1 Aug 2012, 12:59 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|